Read more
This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, Novel Therapeutics for Rare Lymphomas covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.
List of contents
The Hematopathology and Diagnostic Challenges of Rare Lymphomas.- Novel Therapeutics in the Management of Waldenstrom Macroglobulinemia.- Immunotherapy in Hodgkin Lymphoma and other CD30+ Lymphomas.- Chronic Lymphocytic Leukemia with Alterations in TP53.- Mantel Cell Lymphoma.- Current and Emerging Treatment Strategies from Primary Mediastinal B-Cell Lymphoma.- Plasmablastic Lymphoma and Primary Effusion Lymphoma.- Novel Agents in Primary Central Nervous System Lymphoma.- Adult T-Cell Leukemia/Lymphoma.- Extranodal NK/T-Cell Lymphoma.- Anaplastic Large Cell Lymphoma.- Enteropathy-Associated T-Cell Lymphomas.- Hepatosplenic T-Cell Lymphoma.- Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sezary Syndrom.
About the author
Christopher Dittus, DO, MPH
Assistant Professor of Medicine
Division of Hematology/Oncology, Lymphoma Program
University of North Carolina, Chapel Hill
Summary
This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, Novel Therapeutics for Rare Lymphomas covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.
Additional text
“This is a well-written, comprehensive book for those who specialize in lymphomas. Tables, illustrations, and figures allow for easy referencing. … This book is intended for lymphoma specialists and hematologists who see these rare lymphomas. … I highly recommend this book to those who specialize in lymphomas.” (Harsh Rohit Shah, Doody’s Book Reviews, March 20, 2020)
Report
"This is a well-written, comprehensive book for those who specialize in lymphomas. Tables, illustrations, and figures allow for easy referencing. ... This book is intended for lymphoma specialists and hematologists who see these rare lymphomas. ... I highly recommend this book to those who specialize in lymphomas." (Harsh Rohit Shah, Doody's Book Reviews, March 20, 2020)
